For laboratory research use only. Not for human consumption. All compounds referenced in this article are sold by Explicit SARMs solely as reference materials for in-vitro and animal research by qualified professionals. Nothing here is medical advice, and no statement has been evaluated by the FDA. These materials are not intended to diagnose, treat, cure or prevent any disease.
CJC-1295 without DAC, also called modified GRF (1-29), is the short-acting form of the CJC-1295 peptide. These are the questions researchers ask about it most often. Explicit SARMs supplies CJC No DAC 5mg strictly as laboratory reference material.
About the Compound
What is CJC-1295 without DAC?
It is a 29-amino-acid GHRH analog with four amino-acid substitutions that make it more resistant to enzymatic breakdown than native GHRH(1-29). It acts on the GHRH receptor.
How is it different from CJC-1295 with DAC?
The DAC version adds an albumin-binding linker that greatly extends its duration of action. Without DAC, the peptide has a short duration that produces a pulse-like stimulus. See our CJC-1295 with DAC overview.
How is it different from sermorelin?
Sermorelin is the unmodified 1-29 sequence. Modified GRF (1-29) carries substitutions intended to improve stability.
Why is it paired with ipamorelin?
The two act on different receptors: the GHRH receptor for CJC-1295 and the ghrelin receptor for ipamorelin. Our CJC-1295 / ipamorelin overview covers the combination.
Our Products
How is it tested?
Our CJC No DAC comes from US domestic manufacturing with two tests by our manufacturer, plus purity testing by an independent third-party lab. A COA is available on request through our contact page.
Regulatory Questions
Is it approved for human use?
No. It is not approved by the FDA for any indication, and GHRH analogs appear on the World Anti-Doping Agency’s prohibited list.
Do you provide dosing or usage guidance?
No. CJC-1295 without DAC is sold strictly for laboratory research, and we do not provide dosing, administration or usage guidance.